Hiroaki Aino
Hiroaki Aino
Antibody Therapeutics, Infectious Diseases & Microbiology, Drug Discovery & Disease Research Laboratory

Antibody medicines have now become a standardized pharmaceutical modality. With the spread of the production platforms in recent years, their pharmaceutical price per therapeutic cycle has become comparable to other molecular-targeted drugs. Because of their high safety properties and long half-lives, they can be used in cases where small molecule drugs are ineffective or when there is an unmet need.
We pride ourselves on producing antibodies using our special method. Our antibody production technologies and research capabilities are our main strengths and have allowed us to not only obtain membrane proteins but also various types of antibodies against highly elusive targets. We are conducting research to develop revolutionary antibody medicines that we have never seen before.
However, with target depletion, a difficult issue in the discovery and development of antibody medicines, looming over us, efforts to develop antibody medicines cannot be sustained without the cooperation of academia. We strongly believe that sharing our skills, experiences, expertise, and human resources is key to the concerted and stimulating research and development of antibody medicines.

Shinnichi Yokota
Shinnichi Yokota
Oligonucleotide Therapeutics, Medium molecular drug discovery, Medicinal Chemistry Research Laboratory

Oligonucleotide drugs are a new modality capable of aiming at drug targets that were inaccessible with small molecule drugs or antibody medicines, recently attracting a great deal of attention. We at Shionogi are pushing forward with research to develop antisense, siRNA, and miRNA drugs, and nucleic acid adjuvants with a wide range of therapeutic possibilities.
In Shionogi's oligonucleotide drug research, we develop new types of nucleic acid adjuvants that are combined with our proprietary DDS technologies, and are continuing with our research for the development of new modified nucleic acids and DDS technologies. Some of the results include a new nucleic acid DDS technology, which has made it possible to deliver nucleic acids to previously inaccessible tissue. We have great expectations that Shionogi's nucleic acid technologies will offer new solutions for targets for which there has been difficulty in developing drugs in the past. By bringing together new ideas from academia and the nucleic acid technologies from Shionogi, we would like to lay the foundation for the discovery and development of new pharmaceutical products.

Masataka Fumoto
Masataka Fumoto
Head of Peptide Therapeutics 2, Peptide Therapeutics 2, Medium molecular drug discovery, Medicinal Chemistry Research Laboratory

In 2017, Shionogi introduced the Peptide Discovery Platform System (PDPS) from Peptidream Inc. and started the research and development of peptide drugs. Peptides obtained from the PDPS are called "macrocyclic/constrained peptides" of medium molecular weight. They are attracting attention as the next-generation drug discovery and development modality as they have features of both small molecules and antibodies.

By combining the advantages of small molecule drugs that we have been developing with the PDPS, we are constructing our own drug discovery and development platform. With the PDPS, we can obtain highly active macrocyclic/constrained peptide compounds with high probability of success even for targets that were previously difficult to address by conventional drug discovery and development methods. With this being a starting point, we are swiftly proceeding with the research and development of peptide drugs. We are also engaged in the design of small molecule drugs by incorporating findings made in association with the peptide research. We wish to pursue the discovery and development of revolutionary drugs together by inviting ideas from within Shionogi and elsewhere for highly innovative drug targets to place on this new discovery and development platform.